Trial Profile
A Randomized, Controlled, Open Label, Two Arms, Exploratory Study to Evaluate the Effect of Everolimus on Histologically Assessed Fibrosis Progression (Ishak-Knodell) in Liver Transplant Recipients With Recurrent Hepatitis C Viral Infection as Compared to Standard Treatment.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Calcineurin inhibitors; Corticosteroids; Mycophenolate mofetil; Mycophenolate sodium
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms REVERT
- Sponsors Novartis
- 24 May 2014 New trial record